Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Alicia E. Woock"'
Autor:
Alicia E. Woock, Jacqueline M. Grible, Amy L. Olex, J. Chuck Harrell, Patricija Zot, Michael Idowu, Charles V. Clevenger
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Abstract In breast cancer, prolactin-induced activation of the transcription factor STAT5a results from the phosphorylation of STAT5a tyrosine residue 694. However, its role in mammary oncogenesis remains an unsettled debate as STAT5a exhibits functi
Externí odkaz:
https://doaj.org/article/ac88965986da4b14922876d81cbc4694
Autor:
Jacqueline M. Grible, Patricija Zot, Amy L. Olex, Shannon E. Hedrick, J. Chuck Harrell, Alicia E. Woock, Michael O. Idowu, Charles V. Clevenger
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-11 (2021)
Abstract The hormone prolactin (PRL) and its receptor (hPRLr) are significantly involved in breast cancer pathogenesis. The intermediate hPRLr (hPRLrI) is an alternatively-spliced isoform, capable of stimulating cellular viability and proliferation.
Externí odkaz:
https://doaj.org/article/4c18855c6cd74555a97c5428cf615799
Autor:
Michael O. Idowu, Charles V. Clevenger, Jacqueline M. Grible, Patricija Zot, Shannon E. Hedrick, Alicia E Woock, Amy L. Olex, J. Chuck Harrell
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-11 (2021)
NPJ Breast Cancer
NPJ Breast Cancer
The hormone prolactin (PRL) and its receptor (hPRLr) are significantly involved in breast cancer pathogenesis. The intermediate hPRLr (hPRLrI) is an alternatively-spliced isoform, capable of stimulating cellular viability and proliferation. An analog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df6596b4f5a52f0a87f40eb2d78c9588
https://doi.org/10.1038/s41523-021-00243-7
https://doi.org/10.1038/s41523-021-00243-7
Autor:
Charles V. Clevenger, Patricija Zot, Jacqueline M. Grible, Alicia E Woock, J. Chuck Harrell, Idowu Michael
Publikováno v:
Journal of the Endocrine Society
The neuroendocrine hormone prolactin (PRL) and its cognate receptor (PRLr) have been implicated in the pathogenesis of breast cancer. PRL signaling relies on activating kinases such as the tyrosine kinase Jak2 and serine/threonine kinases ERK1/2, Nek
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3d18712c367ff8d94c6f1ed194c439f
https://doi.org/10.1210/jendso/bvaa046.1035
https://doi.org/10.1210/jendso/bvaa046.1035
Autor:
Robert L. Gladding, Alicia E. Woock, Shuiyu Lu, Jeih-San Liow, Rong Xu, Sami S. Zoghbi, Victor W. Pike, Kimberly J. Jenko, Jinsoo Hong, Robert B. Innis
Publikováno v:
Nuclear Medicine and Biology. 42:967-974
Introduction Metabotropic glutamate subtype receptor 1 (mGluR1) is implicated in several neuropsychiatric disorders and is a target for drug development. [ 18 F]FIMX ([ 18 F]4-fluoro-- N -methyl- N --(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)ben
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fcf2bedbba7869f93bb85ca1fecae7f
https://doi.org/10.1016/j.nucmedbio.2015.07.006
https://doi.org/10.1016/j.nucmedbio.2015.07.006
Autor:
H. Umesha Shetty, Alicia E. Woock, Victor W. Pike, Cheryl L. Morse, William C. Kreisl, Ritwik Bhatia, Sami S. Zoghbi, Robert B. Innis
Publikováno v:
Journal of Nuclear Medicine. 56:82-87
The permeability-glycoprotein (P-gp) efflux transporter is densely expressed at the blood–brain barrier, and its resultant spare capacity requires substantial blockade to increase the uptake of avid substrates, blunting the ability of investigators
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6df3798982f02aaac78f9e48d60dd325
https://doi.org/10.2967/jnumed.114.146894
https://doi.org/10.2967/jnumed.114.146894
Autor:
Robert B. Innis, Alicia E. Woock, Victor W. Pike, Rong Xu, Sami S. Zoghbi, Paolo Zanotti-Fregonara, Robert L. Gladding
Publikováno v:
Journal of Medicinal Chemistry. 56:9146-9155
We sought to develop a PET radioligand that would be useful for imaging human brain metabotropic subtype 1 receptors (mGluR1) in neuropsychiatric disorders and in drug development. 4-Fluoro-N-methyl-N-(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0b0324ce4f39e56172b66cc6a50c5ee
https://doi.org/10.1021/jm4012017
https://doi.org/10.1021/jm4012017
Publikováno v:
The FASEB Journal. 27
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b02b4d6327dc6ae46994ec2ed945a87
https://doi.org/10.1096/fasebj.27.1_supplement.732.1
https://doi.org/10.1096/fasebj.27.1_supplement.732.1